SCHEDULE: Lynx1 Capital Discloses 7.3% Stake in C4 Therapeutics

Lynx1 Capital Management LP and Weston Nichols have disclosed a 7.3% beneficial ownership stake in C4 Therapeutics, holding 7,098,133 shares.

Summary

• Lynx1 Capital Management LP and Weston Nichols have filed an Amendment No. 3 to Schedule 13G, disclosing their beneficial ownership in C4 Therapeutics, Inc.
• The reporting persons collectively beneficially own 7,098,133 shares of C4 Therapeutics' Common Stock.
• This ownership represents 7.3% of the company's outstanding Common Stock.
• The percentage is calculated based on 96,914,418 shares outstanding as of October 29, 2025, as reported in C4 Therapeutics' Form 10-Q.
• Lynx1 Capital Management LP is a Delaware limited partnership and the investment manager to Lynx1 Master Fund LP.
• Weston Nichols is the sole member of Lynx1 Capital Management GP LLC, the general partner of Lynx1 Capital Management LP.
• Both reporting persons share voting and dispositive power over all 7,098,133 shares.
• The securities were not acquired for the purpose of changing or influencing control of C4 Therapeutics, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. The disclosure of a significant 7.3% stake by an institutional investor suggests a strong belief in C4 Therapeutics' value, although it is a passive investment.

Positives

• A significant institutional investor, Lynx1 Capital Management LP, has disclosed a substantial 7.3% stake in C4 Therapeutics, indicating confidence in the company's long-term prospects.
• The filing confirms that the investment is passive, not intended to change or influence control, which can provide stability and reduce concerns about activist investor actions.

Negatives

• This filing is a routine disclosure of beneficial ownership and does not contain information about the company's operational or financial performance, thus no direct negatives are present within the filing itself.

Risks

• This filing is a disclosure of beneficial ownership and does not detail specific risks related to C4 Therapeutics, Inc.'s operations or financial health.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from C4 Therapeutics, Inc. or the reporting persons regarding the company's future performance.

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by an institutional investor like Lynx1 Capital Management LP in a biotechnology company such as C4 Therapeutics can signal a vote of confidence in the company's pipeline, technology, or market position. Such investments are often seen as a positive indicator, especially in the volatile biotech sector where long-term capital commitment is crucial. This type of filing does not typically provide insights into broader industry trends but rather reflects an investor's specific conviction in a particular company.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence among existing shareholders and potentially attract new investors, signaling a positive external validation of the company's value.
• Company Management: A large, passive institutional investor can provide a stable shareholder base, reducing immediate pressure for short-term performance and allowing management to focus on long-term strategic goals.

Key Dates

Recommendation

A significant institutional ownership disclosure like this typically signals a positive sentiment from a sophisticated investor, which can be a good sign for the company. However, this filing alone does not provide enough operational or financial data to warrant a 'buy' or 'sell' recommendation. It primarily indicates that a major investor sees value in C4 Therapeutics. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while awaiting further operational updates or financial results from the company.

Keywords

C4 Therapeutics, Lynx1 Capital Management, Weston Nichols, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals